New York, USA-based Regeneron (Nasdaq: REGN) is set to invest around $1.8 billion in its home state, with a major expansion of its research and development facilities.
The money, which could lead to the addition of 1,000 new jobs, will be made at its base in Tarrytown, to the north of New York City.
Announcing the decision, New York Governor Andrew Cuomo said the expansion would help “fuel lifesaving innovation and development that benefits the entire world."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze